Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOMEOSAR
DRKS00018081Phase 4Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of galphimia glauca in allergic rhinitis (AR) and seasonal allergic rhinitis (SAR) (3 arms), sponsored by Charité – Universitätsmedizin Berlin. Started Jun 2020; status: completed.
02
Drugs
galphimia glauca
03
Conditions
allergic rhinitis (AR)seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on DRKS00018081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00018081.